| Literature DB >> 29664915 |
Morteza Seifi1, Michael A Walter1.
Abstract
Mutations in PITX2 have been implicated in several genetic disorders, particularly Axenfeld-Rieger syndrome. In order to determine the most reliable bioinformatics tools to assess the likely pathogenicity of PITX2 variants, the results of bioinformatics predictions were compared to the impact of variants on PITX2 structure and function. The MutPred, Provean, and PMUT bioinformatic tools were found to have the highest performance in predicting the pathogenicity effects of all 18 characterized missense variants in PITX2, all with sensitivity and specificity >93%. Applying these three programs to assess the likely pathogenicity of 13 previously uncharacterized PITX2 missense variants predicted 12/13 variants as deleterious, except A30V which was predicted as benign variant for all programs. Molecular modeling of the PITX2 homoedomain predicts that of the 31 known PITX2 variants, L54Q, F58L, V83F, V83L, W86C, W86S, and R91P alter PITX2's structure. In contrast, the remaining 24 variants are not predicted to change PITX2's structure. The results of molecular modeling, performed on all the PITX2 missense mutations located in the homeodomain, were compared with the findings of eight protein stability programs. CUPSAT was found to be the most reliable in predicting the effect of missense mutations on PITX2 stability. Our results showed that for PITX2, and likely other members of this homeodomain transcription factor family, MutPred, Provean, PMUT, molecular modeling, and CUPSAT can reliably be used to predict PITX2 missense variants pathogenicity.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29664915 PMCID: PMC5903617 DOI: 10.1371/journal.pone.0195971
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Summary of all 31 known pathogenic missense variants in PITX2.
Characterized variants are shown in bold type.
Position, effects on protein function and associated phenotype of previously characterised PITX2 missense variants.
| No | Variant | Exon | Domain | Phenotype | Effect on protein function | Reference |
|---|---|---|---|---|---|---|
| 1 | R43W | 5 | HD | ARS | Reduced DNA-binding and transactivational activity | Idress et al. 2006 [ |
| 2 | H45Q | 5 | HD | CHD | Reduced transactivational activity | Yuan et. 2013 [ |
| 3 | Q49L | 5 | HD | TOF | Reduced transactivational activity | Sun et al. 2016 [ |
| 4 | L54Q | 5 | HD | ARS | Reduced DNA-binding and transactivational activity | Semina et al. 1996 [ |
| 5 | P64S | 5 | HD | AF | Reduced transactivational activity | Wang et al. 2014 [ |
| 6 | M66T | 5 | HD | CHD | Reduced transactivational activity | Yuan et al. 2013 [ |
| 7 | T68P | 5 | HD | ARS | Reduced DNA-binding and transactivational activity | Semina et al. 1996 [ |
| 8 | R69H | 5 | HD | ARS | Reduced DNA-binding activity | Kulak et al. 1998 [ |
| 9 | T76S | 5 | HD | CHD | Reduced transactivational activity | Wei et al. 2014 [ |
| 10 | V83L | 5 | HD | ARS | Reduced DNA-binding activity, but increased transactivational activity | Priston et al. 2001 [ |
| 11 | R84W | 5 | HD | ARS | Reduced DNA binding and transactivational activity | Alward et al. 1998 [ |
| 12 | K88E | 6 | HD | ARS | Reduced DNA binding and transactivational activity | Amendt et al. 2000 [ |
| 13 | R90C | 6 | HD | ARS | Reduced DNA binding and transactivational activity | Perveen et al. 2000 [ |
| 14 | R91P | 6 | HD | ARS | Reduced DNA binding and transactivational activity | Semina et al. 1996 [ |
| 15 | R91Q | 6 | HD | CHD | Reduced transactivational activity | Wei et al. 2014 [ |
| 16 | N100D | 6 | Downstream of HD | CHD | Reduced transactivational activity | Wang et al. 2013 [ |
| 17 | L105V | 6 | Downstream of HD | ARS | Reduced DNA binding activity | Phillips, 2002 [ |
| 18 | N108T | 6 | Downstream of HD | ARS | Reduced DNA-binding activity, but increased transactivational activity | Phillips, 2002 [ |
AF; atrial fibrillation (AF), ARS; Axenfeld-Rieger syndrome (ARS), CHD; congenital heart disease, HD; homeodomain, TOF; tetralogy of Fallot
Amino acid substitution (AAS) prediction methods used in this study.
| Program | Input | Algorithm | Output | URL | Reference |
|---|---|---|---|---|---|
| SIFT | PS and AAS, protein sequence alignment and AAS, dbSNP id, or protein id | Uses sequence homology, scores assessment is based on position-specific scoring matrices with Dirichlet priors | Score ranges from 0 to 1, where < = 0.05 is damaging and >0.05 is tolerated | Ng and Henikoff, 2001 [ | |
| PolyPhen-2 | PS and AAS, dbSNP id, HGVbASE id, or protein id | Uses sequence conservation and structure to model location of amino acid substitution, Swiss-Prot and TrEMBL annotation | Score ranges from 0 to 1, where < = 0.05 is benign, and >0.05 is damaging | Ramensky et al. 2002 [ | |
| PANTHER-PSEP | PS and AAS | Uses sequence homology; scores are based on PANTHER Hidden Markov Model families | Probably damaging: time > 450my possibly damaging: 450my > time > 200my probably benign: time < 200my) | Tang and Thomas, 2016 [ | |
| MutPred | Protein id, PS, or multiple sequence alignment | Prediction is based on one of two neural networks which uses internal databases, secondary structure prediction, and sequence conservation | Score ranges from 0 to 1, where 0 is polymorphism and high scores are predicted to be deleterious/disease-associated | Li et al. 2009 [ | |
| MutatioTaster | DNA sequence | Predictions are calculated by a naive Bayes classifier, which predicts the disease potential | Prediction is based one of four possible types: a) disease causing: probably deleterious b) disease causing automatic: known to be deleterious c) polymorphism: probably harmless d) polymorphism automatic: known to be harmless | Schwarz et al. 2014 [ | |
| Provean | PS and AAS | Uses an alignment-based score approach to generate predictions not only for single amino acid substitutions, but also for multiple amino acid substitutions, and in-frame insertions and deletions | the default score threshold is currently set at -2.5, in which >-2.5 is neutral, and <-2.5 is deleterious | Choi and Chan, 2015 [ | |
| PMUT | PS and AAS, dbSNP, Uniprot or PDB ID of protein | Based on the application of neural networks which uses internal databases, secondary structure prediction, and sequence conservation | Score ranges from 0 to 1, where <0.50 is neutral and >0.50 is disease associated | Ferrer-Costa et al. 2002 [ | |
| FATHMM | protein identifier and the amino acid substitution, dbSNP id | Uses sequence homology | The score threshold is set at -2.5, in which >-2.5 is neutral, and <-2.5 is deleterious | Shihab et al. 2013 [ | |
| nsSNPAnalyzer | Protein sequence in FASTA format and a substitution file denoting the SNP identities to be analyzed | Uses information contained in the multiple sequence alignment and information contained in the three-dimensional protein structure to make predictions. | Normalized probability of the substitution calculated by the SIFT program | Bao et al. 2005 [ | |
| Align GV-GD | Protein sequence in FASTA format and a substitution file denoting the SNP identities to be analyzed | Uses biophysical features of amino acids and protein multiple sequence alignments | A value of C > 0 was considered deleterious; otherwise a variant was neutral | Tavtigian et al. 2006 [ | |
| REVEL | Precomputed REVEL scores are provided for all possible human missense variants | Prediction is based on a combination of scores from 13 individual tools | Score ranges from 0 to 1, where <0.50 is neutral and >0.50 is pathogenic | Ioannidis et al. 2016 [ |
AAS; amino acid sequences, PS; protein sequence, PDB, protein data bank
Protein stability prediction methods used in this study.
| Program | Input | Algorithm | Output | URL | Reference |
|---|---|---|---|---|---|
| DUET | Protein structure | Uses SVM regression with a Radial Basis Function kernel, and RSA | Score ranges from negative to positive numbers, where negative number denote destabilizing, and positive number denote stabilizing | Pires et al. 2014 [ | |
| SDM | Protein structure | Uses conformationally constrained environment-specific substitution tables (ESSTs) | Score ranges from negative to positive numbers, where negative number denote destabilizing, and positive number denote stabilizing | Pandurangan et al. 2017 [ | |
| mCSM | Protein structure | Uses the concept of graph-based structural signatures | Score ranges from negative to positive numbers, where negative number denote destabilizing, and positive number denote stabilizing | Pires et al. 2014 [ | |
| I-Mutant3.0 | Protein sequence alone or protein structure | Using SVM regression with a Radial Basis Function kernel, and RSA | Score ranges from negative to positive numbers, where negative number denote destabilizing, and positive number denote stabilizing | Capriotti et al. 2006 [ | |
| MUpro | Protein sequence | Uses feed-forward neural networks and SVMs | A score near 0 means unchanged stability. Score near -1 means high confidence in decreased stability. Score near +1 means high confidence in increased stability | Cheng et al. 2006 [ | |
| iPTREE-STAB | Protein sequence | Based on the neighboring residues of short window length | Score ranges from negative to positive numbers, where negative number denote destabilizing, and positive number denote stabilizing | Huang et al. 2007 [ | |
| CUPSAT | Existing PDB structures or custom protein structures | Uses structural environment specific atom potentials and torsion angle potentials | Score ranges from negative to positive numbers, where negative number denote destabilizing, and positive number denote stabilizing | Parthiban et al. 2006 [ | |
| iStable | Protein sequence or PDB structure (PDB ID) | Uses SVM | Score ranges from negative to positive numbers, where negative number denote destabilizing, and positive number denote stabilizing | Chen et al. 2013 [ |
RSA; residue relative solvent accessibility, SVM; support vector machine
Functional characterization vs. bioinformatics programs.
Comparison of in silico program predictions of degrees of tolerance for 18 functionally characterized PITX2 missense mutation.
| No | Missense variants | SIFT Score | PolyPhen-2 Score | MutPred Score | MutationTaster Score | Provean Score | PANTHER-PSEP Score | PMUT Score | FATHMM Score | nsSNPAnalyzer Score | Align GV-GD Score | REVEL Score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | R43W | 0 (√) | 0.003 (×) | 0.952 (√) | 101 (√) | -7.125 (√) | PD (√) | 0.91 (√) | -5.53 (√) | 0.00 (√) | C65 (√) | 0.599 (√) |
| 2 | H45Q | 0.21 (×) | 1.000 (√) | 0.672 (√) | 24 (√) | -7.176 (√) | PD (√) | 0.87 (√) | -3.86 (√) | 0.15 (×) | C15 (√) | 0.903 (√) |
| 3 | Q49L | 0.25 (×) | 0.995 (√) | 0.598 (√) | 113 (√) | -6.498 (√) | PD (√) | 0.76 (√) | -3.96 (√) | 0.84 (×) | C65 (√) | 0.555 (√) |
| 4 | L54Q | 0 (√) | 0.997 (√) | 0.959 (√) | 113 (√) | -5.598 (√) | PD (√) | 0.91 (√) | -6.23 (√) | 0.00 (√) | C65 (√) | 0.856 (√) |
| 5 | P64S | 0 (√) | 0.999 (√) | 0.867 (√) | 74 (√) | -7.547 (√) | PD (√) | 0.85 (√) | -5.05 (√) | 0.00 (√) | C65 (√) | 0.908 (√) |
| 6 | M66T | 0 (√) | 0.995 (√) | 0.566 (√) | 81 (√) | -5.555 (√) | PD (√) | 0.88 (√) | -3.64 (√) | 0.01 (√) | C65 (√) | 0.595 (√) |
| 7 | T68P | 0 (√) | 0.946 (√) | 0.854 (√) | 38 (√) | -5.094 (√) | PD (√) | 0.87 (√) | -3.81 (√) | 0.01 (√) | C35 (√) | 0.747 (√) |
| 8 | R69H | 0 (√) | 0.007 (×) | 0.985 (√) | 29 (√) | -4.733 (√) | PD (√) | 0.90 (√) | -4.42 (√) | 0.00 (√) | C25 (√) | 0.752 (√) |
| 9 | T76S | 0 (√) | 0.995 (√) | 0.655 (√) | 58 (√) | -3.652 (√) | PD (√) | 0.89 (√) | -4.01 (√) | 0.01 (√) | C55 (√) | 0.706 (√) |
| 10 | V83L | 0.01 (√) | 0.902 (√) | 0.944 (√) | 32 (√) | -2.758 (√) | PD (√) | 0.89 (√) | -4.91 (√) | 0.14 (×) | C25 (√) | 0.812 (√) |
| 11 | R84W | 0 (√) | 0.994 (√) | 0.841 (√) | 101 (√) | -7.350 (√) | PD (√) | 0.88 (√) | -4.01 (√) | 0.00 (√) | C65 (√) | 0.907 (√) |
| 12 | K88E | 0 (√) | 0.008 (×) | 0.828 (√) | 56 (√) | -3.800 (√) | PD (√) | 0.88 (√) | -3.92 (√) | 0.04 (√) | C55 (√) | 0.725 (√) |
| 13 | R90C | 0 (√) | 0.957 (√) | 0.975 (√) | 180 (√) | -7.599 (√) | PD (√) | 0.91 (√) | -4.45 (√) | 0.00 (√) | C65 (√) | 0.816 (√) |
| 14 | R91P | 0 (√) | 0.998 (√) | 0.959 (√) | 103 (√) | -6.649 (√) | PD (√) | 0.91 (√) | -5.73 (√) | 0.00 (√) | C65 (√) | 0.727 (√) |
| 15 | R91Q | 0 (√) | 0.997 (√) | 0.918 (√) | 43 (√) | -3.800 (√) | PD (√) | 0.91 (√) | -5.71 (√) | 0.00 (√) | C35 (√) | 0.726 (√) |
| 16 | N100D | 0.2 (×) | 0.863 (√) | 0.365 (×) | 23 (√) | -4.013 (√) | PD (√) | 0.81 (√) | -3.65 (√) | 0.20 (×) | C15 (√) | 0.861 (√) |
| 17 | L105V | 0.06 (×) | 0.974 (√) | 0.788 (√) | 32 (√) | -1.894 (×) | PD (√) | 0.80 (√) | -3.16 (√) | 0.27 (×) | C25 (√) | 0.861 (√) |
| 18 | N108T | 0.24 (×) | 0.990 (√) | 0.789 (√) | 65 (√) | -3.332 (√) | PD (√) | 0.68 (√) | -3.05 (√) | 0.35 (×) | C55 (√) | 0.443 (×) |
PD; probably damaging
√ correspond to functional characterization; ×, do not correspond to functional characterization.
In silico analysis of the effect of 16 PITX2 benign variants.
| No | Missense variants | SIFT Score | PolyPhen-2 Score | MutPred Score | MutationTaster Score | Provean Score | PANTHER-PSEP Score | PMUT Score | FATHMM Score | nsSNPAnalyzer Score | Align GV-GD Score | REVEL Score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | P41S | 0.25 (√) | 0.002 (√) | 0.201 (√) | 74 (×) | 0.325 (√) | PD (×) | 0.16 (√) | -2.80 (×) | 0.38 (√) | C65 (×) | 0.237 (√) |
| 2 | Q75P | 0.33 (√) | 0.000 (√) | 0.371 (√) | 76 (×) | -0.065 (√) | PD (×) | 0.14 (√) | -2.77 (×) | 0.27 (√) | C65 (×) | 0.503 (×) |
| 3 | V81M | 0.11 (√) | 0.459 (×) | 0.063 (√) | 21 (√) | -0.023 (√) | PB (√) | 0.08 (√) | -2.74 (×) | 0.14 (√) | C15 (×) | 0.501 (×) |
| 4 | A188T | 0.68 (√) | 0.027 (√) | 0.329 (√) | 58 (×) | -1.018 (√) | PD (×) | 0.04 (√) | -2.86 (×) | 0.57 (√) | C55 (×) | 0.151 (√) |
| 5 | M207V | 0.62 (√) | 0.069 (√) | 0.386 (√) | 21 (×) | -1.461 (√) | PD (×) | 0.15 (√) | -2.61 (×) | 0.47 (√) | C15 (×) | 0.185 (√) |
| 6 | R203C | 0 (×) | 0.968 (×) | 0.150 (√) | 81 (×) | -0.455 (√) | PB (√) | 0.03 (√) | -2.51 (×) | 0.12 (√) | C65 (×) | 0.146 (√) |
| 7 | Q193T | 0.38 (√) | 0.270 (√) | 0.196 (√) | 84 (×) | 0.630 (√) | PD (×) | 0.02 (√) | -.2.60 (×) | 0.00 (×) | C35 (×) | 0.152 (√) |
| 8 | Y131D | 0 (×) | 0.812 (×) | 0.121 (√) | 35 (×) | -0.010 (√) | PD (×) | 0.03 (√) | -1.64 (√) | 0.01 (×) | C65 (×) | 0.251 (√) |
| 9 | G166D | 0 (×) | 0.557 (×) | 0.283 (√) | 76 (×) | -0.357 (√) | PB (√) | 0.31 (√) | -2.58 (×) | 0.01 (×) | C65 (×) | 0.224 (√) |
| 10 | H151Y | 0 (×) | 0.512 (×) | 0.045 (√) | 75 (×) | -2.400 (√) | PD (×) | 0.03 (√) | -2.62 (×) | 0.01 (×) | C65 (×) | 0.169 (√) |
| 11 | I138F | 0 (×) | 0.671 (×) | 0.056 (√) | 57 (×) | -0.390 (√) | PB (√) | 0.2 (√) | -2.69 (×) | 0.04 (×) | C0 (√) | 0.145 (√) |
| 12 | G205S | 0.68 (√) | 0.017 (√) | 0.193 (√) | 87 (×) | -0.372 (√) | PB (√) | 0.15 (√) | -2.62 (×) | 0.78 (√) | C55 (×) | 0.147 (√) |
| 13 | G186R | 0 (×) | 1.000 (×) | 0.212 (√) | 48 (×) | -1.092 (√) | PD (×) | 0.08 (√) | -2.86 (×) | 0.00 (×) | C65 (×) | 0.103 (√) |
| 14 | H57Q | 0 (×) | 0.736 (×) | 0.056 (√) | 63 (×) | -3.010 (×) | PB (√) | 0.03 (√) | -2.55 (×) | 0.00 (×) | C15 (×) | 0.112 (√) |
| 15 | A246D | 0 (×) | 1.000 (×) | 0.440 (√) | 44 (×) | -0.769 (√) | PD (×) | 0.18 (√) | -2.65 (×) | 0.01 (×) | C65 (×) | 0.181 (√) |
| 16 | G148W | 0 (×) | 0.844 (×) | 0.195 (√) | 65 (×) | -0.242 (√) | PB (√) | 0.31 (√) | -2.74 (×) | 0.04 (×) | C65 (×) | 0.109 (√) |
PB; probably benign, PD; probably damaging
√ correspond to functional characterization; ×, do not correspond to functional characterization.
Fig 2Reliability of eleven in silico programs used to analyze all 18 functionally characterized missense variants in PITX2.
True positives (TP) are missense variants correctly predicted to disrupt PITX2 protein function, and false negatives (FN) are those incorrectly predicted to be benign or tolerated. True negatives (TN) are neutral variants correctly predicted as benign or tolerated and false positives (FP) are neutral variants incorrectly predicted to disrupt PITX2 protein function. The total of variants for all methods was 34, 18 pathogenic variants and 16 benign variants. Values were converted to percentage. Values were converted to percentage. The statistics used were calculated as follows: Sensitivity = TP/(TP + FN); Specificity = TN/(TN + FP); Accuracy = (TP + TN)/(TP + TN + FP + FN); Precision = TP/(TP + FP); Negative predictive value (NPV) = TN/(TN + FN); Positive predictive value (PPV) = TP/(TP + FP); Matthews correlation coefficient (MCC) = (TP × TN − FP × FN)/-([TP + FP] × [TP + FN] × [TN + FP] × [TN + FN]R).
Bioinformatics prediction of the degree of tolerance for 13 functionally uncharacterized PITX2 missense variants.
| No | Missense variants | References | Phenotype | Mutpred Score | Provean Score | PMUT Score |
|---|---|---|---|---|---|---|
| 1 | A30V | Zaidi et al. 2013 [ | CHD | B, 0.152 | B, -0.948 | B, 0.10 |
| 2 | S37W | Yang et al. 2013 [ | AF | PD, 0.503 | PD, -1.074 | PD, 0.81 |
| 3 | F58L | Vieira et al. 2006 [ | ARS | PD, 0.947 | PD, -5.560 | PD, 0.90 |
| 4 | R62H | Amendt et al. 2000 [ | ARS | PD, 0.856 | PD, -4.686 | PD, 0.70 |
| 5 | P64L | Phillips JC, 2002 [ | ARS | PD, 0.973 | PD, -9.421 | PD, 0.81 |
| 6 | P64R | Weisschuh et al. 2006 [ | ARS | PD, 0.944 | PD, -8.496 | PD, 0.84 |
| 7 | R69C | Kimura et al. 2014 [ | ARS | PD, 0.960 | PD, -7.575 | PD, 0.91 |
| 8 | V83F | Reis et al. 2012 [ | ARS | PD, 0.912 | PD, -4.643 | PD, 0.91 |
| 9 | W86S | Dandan et al. 2008 [ | ARS | PD, 0.868 | PD, -13.298 | PD, 0.91 |
| 10 | W86C | Reis et al. 2012 [ | ARS | PD, 0.950 | PD, -12.282 | PD, 0.91 |
| 11 | R90P | Phillips JC, 2002 [ | ARS | PD, 0.960 | PD, -6.649 | PD, 0.91 |
| 12 | G137V | Kniestedt et al. 2006 [ | ARS | PD, 0.816 | B, -1.902 | PD, 0.61 |
| 13 | Q297H | Huang et al. 2015 [ | ARS | PD, 0.682 | PD, -3.966 | PD, 0.91 |
AF; atrial fibrillation (AF), ARS; Axenfeld-Rieger syndrome (ARS), ASMD; Anterior segment mesenchymal dysgenesis, B; benign, CHD; congenital heart disease, PD; probably damaging
Fig 3Homology models (left) and scatterplots (right) of in silico analyses of the L54Q, V83L, and R91P variants in the PITX2 gene.
The 3D model of PITX2 is presented with the protein backbone depicted in black ribbon, the co-crystallized DNA binding target in space-filled green model and the mutants positions in red. The wild-type and mutant-equivalent models were analyzed by the atomic nonlocal environment assessment (ANOLEA) server. Peaks on the scatterplots show the positions of amino acids that changed their pseudoenergy state, as a consequence of the mentioned variants.
Fig 4Homology models (left) and scatterplots (right) of in silico analyses of the F58L, V83F, W86C, and W86S variants in the PITX2 gene.
The 3D model of PITX2 is presented with the protein backbone depicted in black ribbon, the co-crystallized DNA binding target in space-filled green model and the mutants positions in red. The wild-type and mutant-equivalent models were analyzed by the atomic nonlocal environment assessment (ANOLEA) server. Peaks on the scatterplots show the positions of amino acids that changed their pseudoenergy state, as a consequence of the mentioned variants.
Evaluation of stability changes of 15 functionally characterized and 9 functionally uncharacterized PITX2 homeodomain missense variants using eight different protein stability prediction programs.
| No. | Variations | DUET | SDM | mCSM | I-Mutant3.0 SEQ | I-Mutant3.0 Structure | MUpro | iPTREE-STAB | CUPSAT | iStable |
|---|---|---|---|---|---|---|---|---|---|---|
| | ||||||||||
| 1 | R43W | -1.773 | 0.35 | -0.97 | 0.00 | -0.13 | -0.162 | 0.0337 | -75.87 | 0.0077 |
| 2 | H45Q | 0.158 | -0.15 | 0.027 | 0.07 | 0.17 | -0.112 | -2.9050 | 19.1 | 0.3529 |
| 3 | Q49L | 0.471 | 0.29 | 0.186 | 0.38 | 0.68 | 1 | 0.9422 | -5.82 | 0.6946 |
| 4 | L54Q | -2.892 | -2.3 | -2.73 | -1.65 | -1.50 | -1 | -1.8488 | 3.85 | -0.9075 |
| 5 | P64S | -2.069 | -1.27 | -1.97 | -1.59 | -1.57 | -1 | -1.0233 | -45.88 | -0.9568 |
| 6 | M66T | 0.444 | -0.67 | 0.181 | -1.20 | -0.32 | -1 | 1.0943 | 10.62 | -0.1104 |
| 7 | T68P | -0.359 | -0.34 | -0.361 | -0.90 | -0.68 | 0.155 | -1.0594 | 0.38 | 0.2945 |
| 8 | R69H | -2.369 | -0.15 | -2.147 | -1.56 | -1.29 | -0.633 | -1.3667 | 8.49 | -0.7126 |
| 9 | T76S | -1.35 | -0.79 | -1.211 | -0.69 | -0.26 | -0.014 | 0.9377 | -16.05 | -0.0892 |
| 10 | V83L | -0.305 | 0.09 | -0.44 | -0.91 | -0.72 | 0.224 | -1.3883 | -2.72 | -0.3060 |
| 11 | R84W | -1.056 | -0.06 | -1.125 | -0.52 | 0.41 | -0.966 | -2.9167 | -23.81 | -0.1240 |
| 12 | K88E | -1.759 | 0.87 | -1.777 | -0.32 | -0.24 | -0.024 | -0.9691 | 8.8 | -0.1765 |
| 13 | R90C | -2.014 | -0.49 | -2.019 | -0.86 | -0.89 | -0.567 | -0.6385 | -19.6 | -0.4268 |
| 14 | R91P | -2.225 | -2.25 | -1.777 | -0.82 | -0.93 | -1 | -2.7464 | -75.47 | -0.6208 |
| 15 | R91Q | -1.308 | -0.08 | -1.3 | -0.95 | -1.04 | -1 | 0.3362 | 37.96 | -0.4777 |
| | ||||||||||
| 1 | F58L | -0.868 | 0.64 | -0.882 | -0.69 | -0.71 | 0.446 | -1.3492 | 8.37 | 0.4267 |
| 2 | R62H | -1.839 | 0.2 | -1.757 | -1.24 | -1.17 | -0.634 | -2.1794 | -1.72 | -0.6073 |
| 3 | P64L | -0.55 | 0.32 | -0.845 | -0.07 | -0.64 | -0.260 | -4.1000 | -5.02 | -0.1755 |
| 4 | P64R | -0.979 | -2.07 | -0.944 | -0.83 | -1.09 | -0.892 | -0.8385 | -13.21 | -0.5091 |
| 5 | R69C | -2.183 | 0.23 | -2.107 | -1.12 | -1.07 | -0.183 | 0.2429 | 0.51 | -0.5278 |
| 6 | V83F | -1.437 | -1.32 | -1.265 | -1.16 | -1.12 | -0.496 | -1.3883 | -10.94 | -0.6159 |
| 7 | W86S | -2.327 | -2.67 | -2.514 | -1.64 | -1.55 | -1 | -0.6167 | -31.26 | -1.0663 |
| 8 | W86C | -0.931 | -1.57 | -1.018 | -1.52 | -1.40 | -0.971 | 0.6923 | -12.15 | -0.8733 |
| 9 | R90P | -1.623 | -2.25 | -1.319 | -0.71 | -0.74 | -0.346 | -2.8825 | -23.89 | -0.3739 |
*Predicted by molecular modeling to destabilize the structure and function of PITX2 protein.